猿猴免疫缺陷病毒对蛋白酶抑制剂的敏感性。
Susceptibilities of simian immunodeficiency virus to protease inhibitors.
作者信息
Giuffre Angelica C, Higgins Joanne, Buckheit Robert W, North Thomas W
机构信息
Center for Comparative Medicine, Department of Veterinary Molecular Biosciences, University of California, Davis, Davis, California 95616, USA.
出版信息
Antimicrob Agents Chemother. 2003 May;47(5):1756-9. doi: 10.1128/AAC.47.5.1756-1759.2003.
Abstract
We used a focal infectivity assay with HeLa H1-JC.37 cells to directly compare susceptibilities of simian immunodeficiency virus (SIV) and human immunodeficiency virus type 1 (HIV-1) to protease inhibitors. SIVmac239 was inhibited by indinavir, saquinavir, and ritonavir, with 50% effective concentrations (means +/- standard deviations) of 39 +/- 8, 55 +/- 3, and 13 +/- 5 nM, respectively. The corresponding values for inhibition of HIV-1 were 66 +/- 4, 47 +/- 10, and 25 +/- 14 nM, respectively.
摘要
我们使用针对HeLa H1-JC.37细胞的局部感染性测定法，直接比较猿猴免疫缺陷病毒（SIV）和1型人类免疫缺陷病毒（HIV-1）对蛋白酶抑制剂的敏感性。茚地那韦、沙奎那韦和利托那韦可抑制SIVmac239，其50%有效浓度（平均值±标准差）分别为39±8、55±3和13±5 nM。抑制HIV-1的相应值分别为66±4、47±10和25±14 nM。
相似文献
1
Susceptibilities of simian immunodeficiency virus to protease inhibitors.猿猴免疫缺陷病毒对蛋白酶抑制剂的敏感性。
Antimicrob Agents Chemother. 2003 May;47(5):1756-9. doi: 10.1128/AAC.47.5.1756-1759.2003.
2
Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.人类免疫缺陷病毒1型蛋白酶抑制剂对白色念珠菌毒力特性的不同衰减作用。
Immunobiology. 1999 Sep;201(1):133-44. doi: 10.1016/S0171-2985(99)80052-7.
3
HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.HIV蛋白酶抑制剂沙奎那韦、茚地那韦和利托那韦：对人肝微粒体中细胞色素P450 3A4介导的睾酮和苯并恶嗪诺里霉素（KRM-1648）代谢的抑制作用。
Toxicol Lett. 1997 Dec;93(2-3):215-9. doi: 10.1016/s0378-4274(97)00098-2.
4
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.HIV蛋白酶抑制剂的临床药理学：聚焦于沙奎那韦、茚地那韦和利托那韦。
Pharm World Sci. 1997 Aug;19(4):159-75. doi: 10.1023/a:1008629608556.
5
Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro.1型人类免疫缺陷病毒蛋白酶抑制剂茚地那韦和沙奎那韦在体外的拮抗作用。
J Infect Dis. 1997 Jul;176(1):265-8. doi: 10.1086/517263.
6
Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.追溯人类免疫缺陷病毒1型对蛋白酶抑制剂耐药性的进化途径：药物不存在和存在时的病毒适应性。
J Virol. 2000 Sep;74(18):8524-31. doi: 10.1128/jvi.74.18.8524-8531.2000.
7
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.与茚地那韦、利托那韦和/或沙奎那韦选择的蛋白酶抑制剂交叉耐药相关的1型人类免疫缺陷病毒蛋白酶切割位点突变。
J Virol. 2001 Jan;75(2):589-94. doi: 10.1128/JVI.75.2.589-594.2001.
8
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.五种人类免疫缺陷病毒（HIV）蛋白酶抑制剂在体外对细胞色素P450 3A4、3A5和3A7的差异抑制作用。
Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85. doi: 10.1111/j.1742-7843.2006.pto_249.x.
9
HIV protease inhibitors.HIV蛋白酶抑制剂。
AIDS. 1996;10 Suppl A:S151-7. doi: 10.1097/00002030-199601001-00021.
10
Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.三种HIV-1蛋白酶抑制剂对美沙酮和丁丙诺啡N-脱烷基化的抑制作用。
Drug Metab Dispos. 1998 Mar;26(3):257-60.
引用本文的文献
1
Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.恒河猴强化抗逆转录病毒疗法可改善RT-SHIV病毒衰减动力学。
Antimicrob Agents Chemother. 2014 Jul;58(7):3927-33. doi: 10.1128/AAC.02522-14. Epub 2014 Apr 28.
2
Can humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders?人源化小鼠能否反映与 HIV 相关的神经认知障碍的复杂病理生物学？
J Neuroimmune Pharmacol. 2012 Jun;7(2):352-62. doi: 10.1007/s11481-011-9335-y. Epub 2012 Jan 7.
3
Simian immunodeficiency virus macaque models of HIV latency.猿猴免疫缺陷病毒猴 HIV 潜伏期模型。
Curr Opin HIV AIDS. 2011 Jan;6(1):57-61. doi: 10.1097/COH.0b013e32834086ce.
4
Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS.艾滋病猕猴模型中高效抗逆转录病毒治疗的病毒衰减动力学。
PLoS One. 2010 Jul 23;5(7):e11640. doi: 10.1371/journal.pone.0011640.
5
Synergistic effect of human CycT1 and CRM1 on HIV-1 propagation in rat T cells and macrophages.人CycT1与CRM1对HIV-1在大鼠T细胞和巨噬细胞中增殖的协同作用。
Retrovirology. 2009 May 12;6:43. doi: 10.1186/1742-4690-6-43.
6
Simian immunodeficiency virus SIVagm dynamics in African green monkeys.非洲绿猴体内的猿猴免疫缺陷病毒SIVagm动态变化
J Virol. 2008 Apr;82(7):3713-24. doi: 10.1128/JVI.02402-07. Epub 2008 Jan 23.
7
Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205.新型小分子进入抑制剂DCM205对1型人类免疫缺陷病毒的直接灭活作用
Antimicrob Agents Chemother. 2007 May;51(5):1780-6. doi: 10.1128/AAC.01001-06. Epub 2007 Feb 16.
8
HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription.对HIV敏感的转基因大鼠可快速对靶向病毒进入或逆转录的抗病毒化合物进行临床前测试。
Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):1015-20. doi: 10.1073/pnas.0607414104. Epub 2007 Jan 5.
9
Ring substituent effects on biological activity of vinyl sulfones as inhibitors of HIV-1.环取代基对作为HIV-1抑制剂的乙烯基砜生物活性的影响。
Bioorg Med Chem. 2007 Jan 15;15(2):1127-37. doi: 10.1016/j.bmc.2006.10.017. Epub 2006 Oct 30.
10
Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.在感染了含有来自1型人类免疫缺陷病毒逆转录酶的重组猿猴免疫缺陷病毒的恒河猴中，通过高效抗逆转录病毒疗法抑制病毒载量。
J Virol. 2005 Jun;79(12):7349-54. doi: 10.1128/JVI.79.12.7349-7354.2005.
本文引用的文献
1
Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.即使在拉米夫定存在的情况下，替诺福韦也能选择出猿猴免疫缺陷病毒逆转录酶中M184V突变的回复突变。
J Virol. 2003 Jan;77(2):1120-30. doi: 10.1128/jvi.77.2.1120-1130.2003.
2
Early and persistent bone marrow hematopoiesis defect in simian/human immunodeficiency virus-infected macaques despite efficient reduction of viremia by highly active antiretroviral therapy during primary infection.尽管在初次感染期间通过高效抗逆转录病毒疗法有效降低了病毒血症，但猿猴/人类免疫缺陷病毒感染的猕猴仍存在早期且持续的骨髓造血缺陷。
J Virol. 2001 Dec;75(23):11594-602. doi: 10.1128/JVI.75.23.11594-11602.2001.
3
Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera.使用高效抗逆转录病毒疗法进行暴露后预防并不能保护猕猴免受SIV/HIV嵌合体的感染。
AIDS. 2000 Aug 18;14(12):1864-6. doi: 10.1097/00002030-200008180-00029.
4
Latent reservoirs of HIV: obstacles to the eradication of virus.HIV的潜伏储存库：根除病毒的障碍。
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):10958-61. doi: 10.1073/pnas.96.20.10958.
5
Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.高效抗逆转录病毒疗法治疗晚期HIV-1疾病后CD4 T细胞功能的持久恢复及病毒载量降低
Lancet. 1998 Jun 6;351(9117):1682-6. doi: 10.1016/s0140-6736(97)10291-4.
6
Transmission of multidrug-resistant human immunodeficiency virus--the wake-up call.
N Engl J Med. 1998 Jul 30;339(5):341-3. doi: 10.1056/NEJM199807303390511.
7
Toward HIV eradication or remission: the tasks ahead.迈向消除或缓解艾滋病毒：未来的任务。
Science. 1998 Jun 19;280(5371):1866-7. doi: 10.1126/science.280.5371.1866.
8
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.成人HIV感染者的抗逆转录病毒药物耐药性检测：对临床管理的影响。国际艾滋病学会美国小组。
JAMA. 1998 Jun 24;279(24):1984-91. doi: 10.1001/jama.279.24.1984.
9
Public health implications of antiretroviral therapy and HIV drug resistance.抗逆转录病毒疗法与HIV耐药性对公共卫生的影响。
JAMA. 1998 Jun 24;279(24):1977-83. doi: 10.1001/jama.279.24.1977.
10
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.CCR5和CD4细胞表面浓度对1型人类免疫缺陷病毒嗜巨噬细胞分离株感染的影响。
J Virol. 1998 Apr;72(4):2855-64. doi: 10.1128/JVI.72.4.2855-2864.1998.
Zotero 插件